The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer

Lung Cancer

Volumn 59, Issue 2, 2008, Pages 232-239

  Zhao, Lujun ^a   Sheldon, Kerby ^a   Chen, Ming ^a   Yin, Moli S ^a   Hayman, James A ^a   Kalemkerian, Gregory P ^b   Arenberg, Doug ^b   Lyons, Susan E ^b,c   Curtis, Jeffrey L ^b,c   Davis, Mary ^a   Cease, Kemp B ^b,c   Brenner, Dean ^b,c   Anscher, Mitchell S ^d   Lawrence, Theodore S ^a   Kong, Feng Ming ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Radiation therapy; Radiation induced lung toxicity; Transforming growth factor 1

Indexed keywords

CARBOPLATIN; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; THROMBOCYTE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIATION INJURIES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 38649099697     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.010     Document Type: Article

References (51)

1. Kupelian P.A., Komaki R., and Allen P. Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 36 (1996) 607-613
2. Sibley G.S., Jamieson T.A., Marks L.B., Anscher M.S., and Prosnitz L.R. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40 (1998) 149-154
3. Rengan R., Rosenzweig K.E., Venkatraman E., Koutcher L.A., Fox J.L., Nayak R., et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 741-747
4. Kong F.M., Ten Haken R.K., Schipper M.J., Sullivan M.A., Chen M., Lopez C., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
5. Chen M., Hayman J.A., Ten Haken R.K., Tatro D., Fernando S., and Kong F.M. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys 64 (2006) 120-126
6. Rosenzweig K.E., Fox J.L., Yorke E., Amols H., Jackson A., Rusch V., et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 103 (2005) 2118-2127
7. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
8. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Douillard J.Y., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10 Suppl. 1 (1994) S239-S244
9. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588. preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
10. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
11. Marino P., Preatoni A., and Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76 (1995) 593-601
12. Curran W.J., Scott C., Langer C., Komaki R., Lee J.S., Hauser S., et al. Phase III comparison of sequential vs. concurrent chemotherapy for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [Abstract]. Proc Am Soc Clin Oncol 19 (2000) 1891
13. Marks L.B., Munley M.T., Bentel G.C., Zhou S.M., Hollis D., Scarfone C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39 (1997) 563-570
14. Kong F.M., Hayman J.A., Griffith K.A., Kalemkerian G.P., Arenberg D., Lyons S., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
15. Hope A.J., Lindsay P.E., El Naqa I., Alaly J.R., Vicic M., Bradley J.D., et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 65 (2006) 112-124
16. Yorke E.D., Jackson A., Rosenzweig K.E., Braban L., Leibel S.A., and Ling C.C. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 672-682
17. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
18. Kwa S.L., Lebesque J.V., Theuws J.C., Marks L.B., Munley M.T., Bentel G., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
19. Rodrigues G., Lock M., D'Souza D., Yu E., and Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 71 (2004) 127-138
20. Anscher M.S., Kong F.M., Marks L.B., Bentel G.C., and Jirtle R.L. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37 (1997) 253-258
21. Anscher M.S., Kong F.M., Andrews K., Clough R., Marks L.B., Bentel G., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41 (1998) 1029-1035
22. Fu X.L., Huang H., Bentel G., Clough R., Jirtle R.L., Kong F.M., et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50 (2001) 899-908
23. Rabbani Z.N., Anscher M.S., Zhang X., Chen L., Samulski T.V., Li C.Y., et al. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 57 (2003) 563-572
24. Nishioka A., Ogawa Y., Mima T., Jin Y.J., Sonobe H., Kariya S., et al. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-beta) receptor mediated by adenoviral vector. Int J Radiat Oncol Biol Phys 58 (2004) 1235-1241
25. Kong F.M., Anscher M.S., Sporn T.A., Washington M.K., Clough R., Barcellos-Hoff M.H., et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49 (2001) 35-41
26. Haiping Z., Takayama K., Uchino J., Harada A., Adachi Y., Kura S., et al. Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene. Cancer Gene Ther 13 (2006) 864-872
27. Larrier N.A., Rabbani Z.N., Chen L., Kang S., Anscher M.A., and Vujaskovic Z. Defining the pathway of radiation induced lung toxicity in mice overexperessing extracellular superoxide dismutase. Int J Radiat Ocol Biol Phys 60 (2004) S328
28. Anscher M.S., Thrasher B., Rabbani Z., Teicher B., and Vujaskovic Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 65 (2006) 876-881
29. Novakova-Jiresova A., Van Gameren M.M., Coppes R.P., Kampinga H.H., and Groen H.J. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71 (2004) 183-189
30. De Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S., and Lebesque J.V. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1378-1387
31. Anscher MS, Kong FM. In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (Int J Radiat Oncol Biol Phys 2004;58:1378-87). Int J Radiat Oncol Biol Phys 2005;61(4):1276-7.
32. Barthelemy-Brichant N. Determination of TGF-beta1 plasma levels: in regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2003;56:988-95) and de Jaeger et al. (Int J Radiat Oncol Biol Phys 2004;58:1378-87). Int J Radiat Oncol Biol Phys 2004;60(4):1339.
33. De Jaeger K., Seppenwoolde Y., Lebesque J.V., and Kampinga H.H. In response to Drs. Anscher and Kong. Int J Radiat Oncol Biol Phys 63 (2005) 308
34. Kong F.M., Anscher M.S., and Jirtle R.L. Transforming growth factor beta: a plasma tumor marker. In: Hanausek M., and Walaszek Z. (Eds). Methods in molecular biology: tumor marker protocols (1997), Human Press Inc., New Jersey 417-430
35. Kong F.M., Washington M.K., Jirtle R.L., and Anscher M.S. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 16 (1996) 47-59
36. Kong F., Jirtle R.L., Huang D.H., Clough R.W., and Anscher M.S. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86 (1999) 1712-1719
37. Kong F.M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., and Jirtle R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222 (1995) 155-162
38. Anscher M.S., Kong F.M., and Jirtle R.L. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 19 (1998) 109-120
39. Bai Y.H., Wang D.W., Cui X.M., Long J.Y., Cui C.B., Jia C.Y., et al. Expression of transforming growth factor beta in radiation interstitial pneumonitis. J Environ Pathol Toxicol Oncol 16 (1997) 15-20
40. Yi E.S., Bedoya A., Lee H., Chin E., Saunders W., Kim S.J., et al. Radiation-induced lung injury in vivo: expression of transforming growth factor-beta precedes fibrosis. Inflammation 20 (1996) 339-352
41. Barthelemy-Brichant N., Bosquée L., Cataldo D., Corhay J.L., Gustin M., Seidel L., et al. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 758-767
42. Kolb M., Willner J., Köberlein E., Hoffmann U., Kirschner J., Flentje M., et al. Autocrine activation of fibroblasts following irradiation. Pneumologie 53 (1999) 296-301
43. Rubin P., Johnston C.J., Williams J.P., McDonald S., and Finkelstein J.N. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33 (1995) 99-109
44. Borst G.R., De Jaeger K., Belderbos J.S., Burgers S.A., and Lebesque J.V. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 62 (2005) 639-644
45. Lind P.A., Wennberg B., Gagliardi G., Rosfors S., Blom-Goldman U., Lidestahl A., et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys 64 (2006) 765-770
46. Claude L., Perol D., Ginestet C., Falchero L., Arpin D., Vincent M., et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71 (2004) 175-181
47. Seppenwoolde Y., De Jaeger K., Boersma L.J., Belderbos J.S., and Lebesque J.V. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 748-758
48. Hernando M.L., Marks L.B., Bentel G.C., Zhou S.M., Hollis D., Das S.K., et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 650-659
49. Arpin D., Perol D., Blay J.Y., Falchero L., Claude L., Vuillermoz-Blas S., et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23 (2005) 8748-8756
50. Chen Y., Hyrien O., Williams J., Okunieff P., Smudzin T., and Rubin P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 62 (2005) 260-266
51. Evans E.S., Kocak Z., Zhou S.M., Kahn D.A., Huang H., Hollis D.R., et al. Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer?. Cytokine 35 (2006) 186-192